{"gene":"KLF13","run_date":"2026-04-28T18:30:27","timeline":{"discoveries":[{"year":2001,"finding":"KLF13 (BTEB3) contains a direct repressor domain in its N-terminus that interacts with co-repressor mSin3A and histone deacetylase HDAC-1, and mediates repression also by competing with Sp1 for binding to GC-rich BTE DNA elements.","method":"Immunoprecipitation, GAL4 fusion assays, gel shift assays, reporter assays in CHO cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — reciprocal Co-IP for mSin3A/HDAC-1 interaction, gel shift for DNA binding competition, functional reporter assays with multiple orthogonal methods in one study","pmids":["11477107"],"is_preprint":false},{"year":2002,"finding":"KLF13 (RFLAT-1) has distinct N-terminal transcriptional activation (aa 1-35) and repression (aa 67-168) domains; contains two independent nuclear localization signals (one upstream of and one within the zinc fingers); binds the critical CTCCC sequence on the RANTES promoter; and synergizes with NF-κB for RANTES transcription.","method":"GAL4 fusion system, deletion analysis, site-directed mutagenesis, GFP fusion NLS mapping, gel shift/mutational analysis, reporter assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal methods including mutagenesis, reporter assays, and direct DNA-binding analysis within one study","pmids":["12050170"],"is_preprint":false},{"year":2002,"finding":"KLF13 (RFLAT-1) protein expression is translationally regulated through its 5'-UTR in a cell-type-specific manner via cap-dependent translation involving eIF4E and its kinase Mnk1, downstream of ERK-1/2 and p38 MAP kinases.","method":"Overexpression of eIF4E, Mnk1 inhibition, kinase pathway inhibitors, quantitative PCR and protein analysis","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal gain/loss-of-function experiments establishing translational regulatory mechanism","pmids":["12093895"],"is_preprint":false},{"year":2003,"finding":"CBP and PCAF co-activators acetylate KLF13 at specific lysine residues in its zinc finger domain; CBP acetylation disrupts KLF13 DNA binding, while PCAF blocks CBP-mediated acetylation to prevent this disruption, and CBP acetylation of KLF13 prevents PCAF stimulation of KLF13 DNA binding—demonstrating antagonistic and synergistic functional interplay between the two acetyltransferases.","method":"In vitro acetylation assays, gel shift assays, site-directed mutagenesis, co-activator co-expression reporter assays","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 — in vitro acetylation with mutagenesis and DNA-binding assays establishing mechanistic details of PTM-dependent regulation","pmids":["12758070"],"is_preprint":false},{"year":2003,"finding":"KLF13 (BTEB3) binds to TGGG repeat motifs in the SM22α promoter and activates or inhibits reporter gene expression depending on which TGGG box it occupies; only one of three boxes is required for BTEB3-dependent activation in P19 cells; KLF13 activates the SM22α promoter in vascular smooth muscle cells (VSMCs) and is expressed in VSMCs in vitro with modulated expression after injury in vivo.","method":"Recombinant protein binding assays, mutation analysis, transient transfection reporter assays in P19 and VSMC cells","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 — mutation analysis and cell-type-specific reporter assays; single lab study","pmids":["12848620"],"is_preprint":false},{"year":2005,"finding":"KLF13 represses the low density lipoprotein receptor (LDLR) promoter by binding proximal LDLR DNA sequences in vivo (confirmed by ChIP) in a DNA context-selective manner; this repression is antagonized by Sp1 and SREBP, and KLF13 binding is upregulated by oxysterols.","method":"RNA interference, EMSA, ChIP, reporter assays, deletion and site-directed mutagenesis, HDAC inhibitor treatment","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including ChIP (in vivo binding), EMSA, RNAi, and mutagenesis in one study","pmids":["16303770"],"is_preprint":false},{"year":2006,"finding":"KLF13 binds conserved regulatory elements on cardiac promoters, activates cardiac transcription, and physically and functionally interacts with GATA-4 to synergistically activate cardiac gene expression; knockdown of KLF13 in Xenopus embryos causes atrial septal defects and hypotrabeculation similar to GATA-4 hypomorphs.","method":"Xenopus knockdown (morpholino), co-immunoprecipitation, reporter assays, in situ hybridization, promoter binding assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1-2 — physical interaction confirmed by Co-IP, functional synergy by reporter assay, and in vivo loss-of-function phenotype with epistasis to GATA-4","pmids":["17053787"],"is_preprint":false},{"year":2008,"finding":"KLF13 deficiency in mice causes accumulation of DP thymocytes, reduction of CD4+ SP cells, altered surface expression of CD3, CD8, CD5, and HSA on DP cells consistent with TCR signaling defects, impaired peripheral T cell activation, a partial block at the CD43+ to CD43− pre-B cell transition, and increased CD21/CD23 expression on peripheral B cells.","method":"KLF13 knockout mice, flow cytometry, cell surface marker analysis","journal":"Cell cycle (Georgetown, Tex.)","confidence":"High","confidence_rationale":"Tier 2 — clean KO with multiple defined cellular phenotypes across B and T cell developmental checkpoints","pmids":["18604172"],"is_preprint":false},{"year":2010,"finding":"miR-125a directly targets the 3'-UTR of KLF13 mRNA (confirmed by luciferase reporter), negatively regulates KLF13 protein expression in a dose-dependent manner, and thereby suppresses RANTES expression in activated T cells.","method":"Luciferase reporter assay, gain- and loss-of-function miRNA transfection, qPCR, ELISA","journal":"Arthritis and rheumatism","confidence":"High","confidence_rationale":"Tier 2 — luciferase reporter validation with multiple gain/loss-of-function methods; replicated across conditions","pmids":["20589685"],"is_preprint":false},{"year":2010,"finding":"KLF13 participates in uterine stromal cell differentiation through cross-regulation with BMP2 and KLF9: KLF13 knockdown attenuates BMP2 expression and abrogates BMP2-mediated inhibition of KLF9, while KLF13 expression is positively associated with BMP2 and inversely with KLF9.","method":"siRNA knockdown in human endometrial stromal cells (HESCs), recombinant BMP2 treatment, KLF9 null mice, qPCR","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — siRNA with in vivo mouse null corroboration; single lab","pmids":["20410205"],"is_preprint":false},{"year":2011,"finding":"KLF13 is required in BALB/c mice for maintenance of IL-4-generating invariant NKT (iNKT) cells; KLF13-deficient BALB/c mice have iNKT cell numbers comparable to C57BL/6 mice and extremely low levels of thymic memory-like CD8+ T cells, demonstrating that KLF13 sustains iNKT cells that produce IL-4 sufficient to drive thymic memory-like CD8+ T cell generation.","method":"KLF13 knockout mice (BALB/c background), flow cytometry, IL-4 neutralization, IL-4 supplementation","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — clean KO with multiple functional rescue experiments establishing pathway position","pmids":["21482696"],"is_preprint":false},{"year":2012,"finding":"KLF13 protein is degraded in resting human T lymphocytes via GSK3β-mediated phosphorylation that triggers ubiquitination by the E3 ligase Fbw7γ; proteasomal or lysosomal inhibition stabilizes KLF13 and increases RANTES expression. This mechanism is absent in murine T cells due to lack of Fbw7γ.","method":"Proteasomal/lysosomal inhibitor treatment, GSK3β and Fbw7γ siRNA knockdown, protein analysis by western blot","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — identification of specific kinase (GSK3β) and E3 ligase (Fbw7γ) with siRNA knockdown validation and species comparison","pmids":["22797700"],"is_preprint":false},{"year":2014,"finding":"KLF13 directly binds IL-4 promoter regions and synergizes with the transcription factor c-Maf to positively regulate IL-4 expression in CD4+ T cells; KLF13-deficient mice show reduced IL-4 and Th2 cytokine gene expression without changes in GATA3 or c-Maf levels.","method":"KLF13 knockout mice, gene expression analysis, ChIP (promoter binding), reporter/synergy assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — KO mice with direct promoter binding demonstrated by ChIP and functional synergy assays","pmids":["24821970"],"is_preprint":false},{"year":2015,"finding":"KLF13 promotes porcine adipocyte differentiation by directly binding to a KLF13-binding site within the −593/−577 region of the porcine PPARγ proximal promoter and transactivating PPARγ expression; siRNA knockdown of KLF13 attenuates porcine adipocyte differentiation.","method":"siRNA knockdown, KLF13 overexpression, promoter deletion and mutation analysis, luciferase reporter assay","journal":"Cell & bioscience","confidence":"Medium","confidence_rationale":"Tier 2 — promoter mutagenesis and reporter assays identifying binding site; single lab, porcine model","pmids":["26085920"],"is_preprint":false},{"year":2016,"finding":"KLF13 is upregulated in HPV-positive keratinocytes via HPV E7 protein suppression of ubiquitin ligase FBW7; KLF13 is required for HPV productive life cycle by supporting STAT5 expression, which activates the ATM DNA damage pathway and IL-8 chemokine; neutralization of IL-8 diminishes viral genome amplification.","method":"shRNA knockdown, qPCR, western blot, viral genome amplification assays, IL-8 neutralization","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — shRNA knockdown with defined pathway placement (KLF13→STAT5→ATM/IL-8→viral genome amplification); single lab","pmids":["27041562"],"is_preprint":false},{"year":2017,"finding":"KLF13 physically interacts with TBX5 via TBX5's T-domain and synergistically activates transcription of cardiac genes; disease-causing TBX5 mutations in the T-domain reduce KLF13 interaction; loss of one Klf13 allele in Tbx5 heterozygous mice significantly increases penetrance of cardiac septal defects.","method":"Co-immunoprecipitation, reporter synergy assays, genetic epistasis in double-heterozygous mice, mutagenesis","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1-2 — reciprocal Co-IP for physical interaction, mutagenesis of disease alleles, and in vivo genetic epistasis in double-heterozygous mice","pmids":["28164238"],"is_preprint":false},{"year":2019,"finding":"The antibiotic clofoctol upregulates KLF13 expression through its targeted binding protein UNR (Upstream of N-ras), an RNA-binding protein; elevated KLF13 acts as a tumor suppressor to inhibit glioma stem cell proliferation and induce apoptosis.","method":"High-throughput drug screening, target binding protein identification, downstream gene analysis, patient-derived xenografts, colony formation and apoptosis assays","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 — identification of UNR as drug target mediating KLF13 upregulation with in vivo xenograft validation; single lab","pmids":["31112526"],"is_preprint":false},{"year":2020,"finding":"KLF13 transcriptionally inhibits HMGCS1 promoter activity (confirmed by ChIP-qPCR and luciferase assay), reducing cholesterol biosynthesis in colorectal cancer cells; KLF13 knockdown or HMGCS1 overexpression rescues proliferation, establishing KLF13→HMGCS1→cholesterol biosynthesis as the tumor-suppressive mechanism.","method":"ChIP-qPCR, luciferase reporter assay, siRNA knockdown, overexpression, CCK-8, colony formation, cell cycle analysis, xenograft","journal":"Cell & bioscience","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP confirms in vivo promoter binding; functional rescue experiments; single lab","pmids":["32523679"],"is_preprint":false},{"year":2023,"finding":"KLF13 recruits a repressor complex comprising SIN3A and HDAC1 to TGF-β target gene promoters, limiting their profibrotic induction; TGF-β transiently induces KLF13 as a negative feedback loop, but persistent TGF-β signaling reduces KLF13 through FBXW7-mediated ubiquitination degradation and HDAC-dependent transcriptional inhibition.","method":"KLF13 global knockout mice, AAV-mediated overexpression, ChIP, Co-IP for SIN3A/HDAC1 complex, reporter assays, FBXW7 interaction studies","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1-2 — KO mice with AAV rescue, Co-IP for repressor complex, ChIP for promoter binding, and identification of FBXW7 as E3 ligase; multiple orthogonal methods","pmids":["37029927"],"is_preprint":false},{"year":2023,"finding":"KLF13 directly regulates expression of JAK/STAT pathway genes (Jak1, Jak2, Jak3, Socs1) by binding their proximal promoters; KLF13 differentially modulates GH-induced JAK/STAT signaling by decreasing the STAT3 branch while enhancing STAT5 activity; GH treatment increases nuclear KLF13 content and Klf13 mRNA.","method":"ChIP, KLF13-deficient HT22 neuronal cells, qPCR, reporter assays, GH stimulation experiments","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP confirms promoter binding; KO cell line functional analysis; single lab","pmids":["37446365"],"is_preprint":false},{"year":2024,"finding":"KLF13 directly binds the SM22α promoter to suppress its expression, promoting vascular smooth muscle cell (VSMC) phenotypic dedifferentiation; KLF13 knockdown ameliorates intimal hyperplasia after carotid injury, at least partly through inactivation of p-AKT signaling.","method":"Bioinformatics, atherosclerotic plaque analysis (human and ApoE−/− mice), siRNA knockdown, ChIP, reporter assay, carotid injury mouse model","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and reporter confirm direct promoter binding; in vivo mouse model; single lab","pmids":["38634445"],"is_preprint":false},{"year":2024,"finding":"KLF13 represses Dll4 transcription (confirmed by luciferase reporter assay), inhibiting the Dll4-Notch2 axis and thereby preventing muscle atrophy; dexamethasone inhibits KLF13 expression by suppressing MYOD1-mediated KLF13 transcriptional activation and promoting FBXW7-mediated KLF13 ubiquitination.","method":"Transcriptome analysis, luciferase reporter assays, KLF13 KO and overexpression in cell and mouse models, MYOD1 interaction analysis","journal":"Journal of cachexia, sarcopenia and muscle","confidence":"Medium","confidence_rationale":"Tier 2 — reporter assay confirms Dll4 as direct target; FBXW7/MYOD1 regulatory pathway identified; in vivo mouse models; single lab","pmids":["38973459"],"is_preprint":false},{"year":2024,"finding":"KLF13 physically interacts with PGC-1α (confirmed by Co-IP) to regulate mitochondrial quality control in alveolar epithelial cells; KLF13 overexpression reduces LPS-induced inflammation and apoptosis, and PGC-1α knockdown reverses these protective effects.","method":"Co-immunoprecipitation, KLF13 overexpression, PGC-1α siRNA, MitoSOX staining, JC-1 staining, western blot","journal":"Journal of interferon & cytokine research","confidence":"Medium","confidence_rationale":"Tier 2-3 — Co-IP identifies PGC-1α as binding partner; functional rescue establishes pathway; single lab","pmids":["38949897"],"is_preprint":false},{"year":2025,"finding":"KLF13 directly binds the GPX4 promoter (by ChIP and dual-luciferase assay) to inhibit GPX4 transcription, thereby promoting ferroptosis in lung adenocarcinoma; overexpression of GPX4 reverses KLF13-induced ferroptosis sensitization.","method":"ChIP assay, dual-luciferase reporter assay, stable overexpression/knockdown cell lines, ROS detection, cytotoxicity assays, xenograft model","journal":"BMC biology","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and reporter confirm direct promoter binding; functional rescue by GPX4 re-expression; single lab","pmids":["40597044"],"is_preprint":false},{"year":2025,"finding":"KLF13 directly binds the CES2 promoter to transcriptionally activate CES2 expression; this transcriptional activation is dependent on acetylation of KLF13 by the co-activator p300, as shown by mutagenesis and p300 inhibition; the KLF13-CES2 axis controls cellular sensitivity to irinotecan in gastric cancer.","method":"ChIP, dual-luciferase reporter assay, site-directed mutagenesis of acetylation sites, p300 inhibition, irinotecan sensitivity assays","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 1-2 — ChIP, reporter assay, and mutagenesis establish direct promoter binding and p300-dependent acetylation mechanism; single lab","pmids":["41438085"],"is_preprint":false},{"year":2025,"finding":"FBXW5 promotes ubiquitin-mediated degradation of KLF13 (confirmed by CoIP); reduced KLF13 releases transcriptional repression of TROAP, facilitating EMT in lung adenocarcinoma; KLF13 directly represses TROAP transcription as shown by ChIP and luciferase assays.","method":"Co-immunoprecipitation, ChIP, dual luciferase reporter assay, siRNA/overexpression, western blot, xenograft model","journal":"Molecular carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 — CoIP identifies FBXW5 as E3 ligase; ChIP and reporter confirm TROAP as direct KLF13 target; single lab","pmids":["40696794"],"is_preprint":false},{"year":2025,"finding":"KLF13 transcriptionally represses SH2B1 expression by binding its promoter, which abolishes the SH2B1-IRS1 protein interaction (confirmed by Co-IP and GST pulldown), thereby repressing PI3K/AKT-mediated glycolysis in NSCLC cells.","method":"ChIP, dual-luciferase reporter assay, EMSA, Co-IP, GST pulldown, glycolysis assays (OCR, ECAR), xenograft model","journal":"Clinical and translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP/EMSA confirm direct promoter binding; Co-IP and GST pulldown validate SH2B1-IRS1 interaction disruption; single lab","pmids":["41410190"],"is_preprint":false},{"year":2025,"finding":"KLF13 directly promotes GPIHBP1 transcription (confirmed by luciferase and ChIP assays), regulating triacylglyceride and free fatty acid metabolism, and promoting esophageal cancer progression through this axis.","method":"RNA-seq, ChIP-seq, ChIP-qPCR, luciferase assay, shRNA and overexpression recovery assays, xenograft model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP-seq and ChIP-qPCR with luciferase validation; functional rescue assays; single lab","pmids":["40450000"],"is_preprint":false},{"year":2025,"finding":"KLF13 promotes HTRA1 transcription (by ChIP-seq and luciferase assays) and activates the Hedgehog signaling pathway to drive breast cancer aggressiveness and immune evasion; HTRA1 overexpression rescues the anti-tumor effects of KLF13 silencing.","method":"ChIP-seq, luciferase assay, RNA-seq, siRNA knockdown, overexpression, in vivo xenograft","journal":"Breast cancer (Tokyo, Japan)","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP-seq and luciferase confirm HTRA1 as direct target; HTRA1 rescue experiment establishes epistasis; single lab","pmids":["40555914"],"is_preprint":false},{"year":2025,"finding":"KLF13 acts as a transcriptional repressor of KLF target genes in maturing neocortical neurons, functioning as part of a transcriptional 'switch' from KLF activators (Klf6, Klf7) to repressors (Klf9, Klf13) that represses shared cytoskeletal targets including Tubb2b and Dpysl3 during postnatal neuronal maturation.","method":"Multiplexed CRISPRi knockdown in mouse neocortical neurons, chromatin accessibility analysis, gene expression profiling","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — CRISPRi with chromatin accessibility and gene expression readouts; preprint not yet peer-reviewed","pmids":["bio_10.1101_2025.02.07.636951"],"is_preprint":true}],"current_model":"KLF13 is a Krüppel-like zinc-finger transcription factor that functions predominantly as a transcriptional repressor (via recruitment of mSin3A/HDAC1 co-repressor complexes and competition with Sp1) but also as an activator depending on promoter context; its activity is regulated post-translationally by CBP/PCAF acetylation of the zinc finger domain, GSK3β-mediated phosphorylation triggering Fbw7γ-dependent ubiquitination and degradation, and FBXW5-mediated ubiquitination; it physically interacts with cardiac co-regulators GATA-4 and TBX5 to synergistically drive cardiac gene expression, and translationally it is controlled through a 5'-UTR rheostat involving eIF4E and MAPK signaling, collectively enabling precise temporal regulation of downstream targets including RANTES/CCL5, IL-4, cardiac structural genes, HMGCS1, GPX4, and others across immune, cardiac, and epithelial cell contexts."},"narrative":{"teleology":[{"year":2001,"claim":"Establishing that KLF13 is a direct transcriptional repressor resolved how this Krüppel-like factor silences GC-rich promoters: through an N-terminal repressor domain that recruits the mSin3A–HDAC1 co-repressor complex and competition with Sp1 for DNA binding.","evidence":"Co-IP, GAL4 fusion/reporter assays, and gel shift in CHO cells","pmids":["11477107"],"confidence":"High","gaps":["Whether mSin3A/HDAC1 recruitment is required at all endogenous KLF13 target promoters","No genome-wide target identification at this stage"]},{"year":2002,"claim":"Mapping of separable activation and repression domains, dual nuclear localization signals, and the critical RANTES promoter binding site established KLF13 as a modular transcription factor with context-dependent output, while the concurrent discovery of 5′-UTR-mediated translational control via eIF4E and MAPK signaling revealed a major post-transcriptional layer governing KLF13 protein levels.","evidence":"GAL4 deletion/mutagenesis, GFP-NLS mapping, gel shift, reporter assays; eIF4E overexpression, Mnk1/MAPK inhibitors, qPCR/protein analysis in T cells","pmids":["12050170","12093895"],"confidence":"High","gaps":["Relative contribution of translational vs. post-translational control in different cell types","Identity of RNA-binding proteins mediating 5′-UTR regulation"]},{"year":2003,"claim":"Demonstrating that CBP and PCAF acetylate KLF13's zinc finger domain with opposing effects on DNA binding established that post-translational acetylation serves as a molecular switch modulating KLF13 transcriptional activity.","evidence":"In vitro acetylation assays, gel shifts, site-directed mutagenesis, co-activator co-expression reporter assays","pmids":["12758070"],"confidence":"High","gaps":["In vivo acetylation dynamics at endogenous targets","Whether acetylation status differs between activation and repression contexts"]},{"year":2005,"claim":"ChIP-based demonstration that KLF13 binds the LDLR promoter in vivo, repressing it in a manner antagonized by Sp1/SREBP and upregulated by oxysterols, placed KLF13 within cholesterol homeostasis pathways and validated the Sp1-competition model at an endogenous locus.","evidence":"ChIP, EMSA, RNAi, reporter assays, HDAC inhibitor treatment","pmids":["16303770"],"confidence":"High","gaps":["Systemic lipid phenotype in KLF13 knockout animals","Interplay with other KLFs on lipid-related promoters"]},{"year":2006,"claim":"Discovery that KLF13 physically interacts with GATA-4 and synergistically activates cardiac gene expression, and that KLF13 morpholino knockdown in Xenopus causes atrial septal defects, established KLF13 as a cardiac transcription factor essential for heart morphogenesis.","evidence":"Co-IP, reporter synergy assays, Xenopus morpholino knockdown, in situ hybridization","pmids":["17053787"],"confidence":"High","gaps":["Cardiac phenotype in mammalian KLF13 knockouts not yet reported at this time","Whether KLF13 mutations cause human congenital heart disease"]},{"year":2008,"claim":"KLF13 knockout mice revealed that KLF13 is required for normal T cell maturation (DP-to-SP transition), peripheral T cell activation, and B cell development, establishing broad immune system functions beyond the previously known RANTES regulation.","evidence":"KLF13 knockout mice, flow cytometry, surface marker analysis","pmids":["18604172"],"confidence":"High","gaps":["Direct transcriptional targets mediating each immune checkpoint defect","Redundancy with other KLF family members in immune cells"]},{"year":2010,"claim":"Identification of miR-125a as a direct negative regulator of KLF13 mRNA via its 3′-UTR added a microRNA-mediated layer to KLF13 regulation and linked dysregulated KLF13/RANTES to autoimmune pathology in SLE T cells.","evidence":"Luciferase reporter, gain/loss-of-function miRNA transfection, ELISA in activated T cells","pmids":["20589685"],"confidence":"High","gaps":["Whether other miRNAs cooperatively regulate KLF13","In vivo confirmation of miR-125a–KLF13 axis in autoimmune models"]},{"year":2011,"claim":"Demonstrating that KLF13 maintains IL-4-producing iNKT cells in BALB/c mice, and that KLF13 deficiency phenocopies IL-4 neutralization for thymic memory CD8+ T cell generation, positioned KLF13 upstream of IL-4 in a strain-specific innate-adaptive immune circuit.","evidence":"KLF13 KO on BALB/c background, IL-4 neutralization and supplementation, flow cytometry","pmids":["21482696"],"confidence":"High","gaps":["Whether KLF13 directly drives IL-4 transcription or acts indirectly through iNKT cell survival"]},{"year":2012,"claim":"Identification of GSK3β-mediated phosphorylation followed by Fbw7γ-dependent ubiquitination as the mechanism controlling KLF13 protein degradation in resting human T cells revealed the primary post-translational destruction pathway and explained species-specific differences in RANTES kinetics.","evidence":"Proteasomal/lysosomal inhibitors, GSK3β and Fbw7γ siRNA, western blot in human vs. murine T cells","pmids":["22797700"],"confidence":"High","gaps":["Precise phosphodegron residues on KLF13","Whether Fbw7α/β isoforms also target KLF13 in non-lymphoid tissues"]},{"year":2014,"claim":"ChIP-confirmed direct binding of KLF13 to IL-4 promoter regions, combined with synergy with c-Maf, resolved the earlier question of whether KLF13 directly activates IL-4 transcription in CD4+ T cells.","evidence":"KLF13 KO mice, ChIP, reporter/synergy assays, gene expression analysis","pmids":["24821970"],"confidence":"High","gaps":["Whether KLF13 regulates IL-4 in iNKT cells through the same mechanism as in CD4+ T cells","Genome-wide KLF13 binding landscape in T cells"]},{"year":2017,"claim":"Physical interaction of KLF13 with TBX5 and genetic epistasis in double-heterozygous mice linked KLF13 to Holt-Oram syndrome biology and demonstrated that KLF13 haploinsufficiency sensitizes to cardiac septal defects in the Tbx5 heterozygous background.","evidence":"Co-IP, reporter synergy assays, disease-causing TBX5 mutagenesis, Klf13+/−;Tbx5+/− double-heterozygous mice","pmids":["28164238"],"confidence":"High","gaps":["Whether human KLF13 mutations cause congenital heart disease independently","Structural basis of the KLF13–TBX5 interaction"]},{"year":2020,"claim":"ChIP-confirmed direct repression of HMGCS1 by KLF13 established a cholesterol biosynthesis–dependent tumor-suppressive mechanism in colorectal cancer, expanding the functional repertoire from LDLR regulation to mevalonate pathway control.","evidence":"ChIP-qPCR, luciferase assay, siRNA knockdown, overexpression rescue, xenograft","pmids":["32523679"],"confidence":"Medium","gaps":["Whether KLF13 coordinately represses multiple mevalonate pathway genes","Confirmation in independent cohorts or labs"]},{"year":2023,"claim":"Demonstration that KLF13 recruits SIN3A–HDAC1 to TGF-β target gene promoters as a negative feedback brake on fibrosis, and that persistent TGF-β signaling degrades KLF13 via FBXW7, unified the repressor complex and ubiquitination mechanisms into a coherent anti-fibrotic circuit.","evidence":"KLF13 global KO mice, AAV-mediated rescue, Co-IP for SIN3A/HDAC1, ChIP, FBXW7 interaction studies","pmids":["37029927"],"confidence":"High","gaps":["Tissue-specific fibrotic phenotypes in KLF13 KO mice beyond those tested","Whether KLF13 loss contributes to human fibrotic diseases"]},{"year":2024,"claim":"Discovery that KLF13 directly represses Dll4 transcription to inhibit the Dll4-Notch2 axis in muscle, and that dexamethasone degrades KLF13 via FBXW7 while also suppressing MYOD1-driven KLF13 transcription, revealed KLF13 as a protective factor against glucocorticoid-induced muscle atrophy.","evidence":"KLF13 KO and overexpression in cell and mouse models, luciferase reporter, MYOD1 interaction analysis","pmids":["38973459"],"confidence":"Medium","gaps":["Whether FBXW7 targets the same phosphodegron as in T cells","In vivo rescue of dexamethasone atrophy by KLF13 overexpression not independently confirmed"]},{"year":2025,"claim":"Multiple concurrent studies identified new direct KLF13 targets (GPX4, CES2, TROAP, SH2B1, GPIHBP1, HTRA1) across cancer types, and identified FBXW5 as an additional E3 ligase for KLF13, broadening the target repertoire to ferroptosis, drug metabolism, EMT, glycolysis, and lipid metabolism while expanding the ubiquitin ligase landscape.","evidence":"ChIP/ChIP-seq, luciferase assays, Co-IP for FBXW5, functional rescue experiments, xenograft models across lung, gastric, esophageal, and breast cancer lines","pmids":["40597044","41438085","40696794","41410190","40450000","40555914"],"confidence":"Medium","gaps":["Most findings from single labs; independent replication needed","Genome-wide ChIP-seq in normal tissues to distinguish direct from cancer-context targets","Structural basis for KLF13 recognition by FBXW5 vs. FBXW7"]},{"year":null,"claim":"A unified genome-wide map of KLF13 binding across tissues, the structural basis for promoter-context-dependent activation versus repression switching, and whether human KLF13 loss-of-function variants cause congenital heart disease or immunodeficiency remain unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No crystal or cryo-EM structure of KLF13 alone or in complex","No human genetics study identifying causative KLF13 mutations in disease","No systematic comparison of KLF13 vs. KLF9 target overlap genome-wide"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,1,4,5,6,12,17,23]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,5,6,12,13,17,18,23,24,25,26,27,28,29]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,5,19]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[7,8,10,12]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[6,15]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[19,26]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[3,11,21,25]}],"complexes":["SIN3A–HDAC1 co-repressor complex"],"partners":["SIN3A","HDAC1","GATA4","TBX5","FBXW7","FBXW5","PGC1A","CBP"],"other_free_text":[]},"mechanistic_narrative":"KLF13 is a Krüppel-like zinc-finger transcription factor that functions as both a transcriptional activator and repressor in a promoter- and cell-type-dependent manner, orchestrating gene programs in immune cell development, cardiac morphogenesis, lipid metabolism, neuronal maturation, and tumor suppression. KLF13 represses target genes by recruiting a SIN3A–HDAC1 co-repressor complex and by competing with Sp1 for GC-rich DNA elements, while it activates transcription through synergistic interactions with GATA-4, TBX5, c-Maf, and p300/PCAF-mediated acetylation [PMID:11477107, PMID:17053787, PMID:28164238, PMID:24821970, PMID:41438085]. KLF13 protein abundance is tightly regulated post-translationally by GSK3β-mediated phosphorylation triggering FBXW7-dependent proteasomal degradation, by FBXW5-mediated ubiquitination, and translationally through a 5′-UTR mechanism involving eIF4E and MAPK signaling [PMID:22797700, PMID:40696794, PMID:12093895]. In vivo, KLF13 deficiency causes atrial septal defects and hypotrabeculation in Xenopus, exacerbates cardiac septal defects when combined with Tbx5 haploinsufficiency in mice, impairs T and B cell development, reduces IL-4 and Th2 cytokine production, and disrupts iNKT cell maintenance [PMID:17053787, PMID:28164238, PMID:18604172, PMID:21482696, PMID:24821970]."},"prefetch_data":{"uniprot":{"accession":"Q9Y2Y9","full_name":"Krueppel-like factor 13","aliases":["Basic transcription element-binding protein 3","BTE-binding protein 3","Novel Sp1-like zinc finger transcription factor 1","RANTES factor of late activated T-lymphocytes 1","RFLAT-1","Transcription factor BTEB3","Transcription factor NSLP1"],"length_aa":288,"mass_kda":31.2,"function":"Transcription factor that activates expression from GC-rich minimal promoter regions, including genes in the cells of the erythroid lineage (By similarity). Represses transcription by binding to the BTE site, a GC-rich DNA element, in competition with the activator SP1. It also represses transcription by interacting with the corepressor Sin3A and HDAC1 (PubMed:11477107). Activates RANTES and CCL5 expression in T-cells (PubMed:17513757)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9Y2Y9/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/KLF13","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/KLF13","total_profiled":1310},"omim":[{"mim_id":"612024","title":"OTU DOMAIN-CONTAINING PROTEIN 7A; OTUD7A","url":"https://www.omim.org/entry/612024"},{"mim_id":"612001","title":"CHROMOSOME 15q13.3 DELETION SYNDROME","url":"https://www.omim.org/entry/612001"},{"mim_id":"608613","title":"TRANSCRIPTION FACTOR Sp6; SP6","url":"https://www.omim.org/entry/608613"},{"mim_id":"605328","title":"KLF TRANSCRIPTION FACTOR 13; KLF13","url":"https://www.omim.org/entry/605328"},{"mim_id":"603301","title":"KLF TRANSCRIPTION FACTOR 11; KLF11","url":"https://www.omim.org/entry/603301"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/KLF13"},"hgnc":{"alias_symbol":["RFLAT-1","BTEB3","NSLP1","FKLF-2"],"prev_symbol":[]},"alphafold":{"accession":"Q9Y2Y9","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y2Y9","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y2Y9-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y2Y9-F1-predicted_aligned_error_v6.png","plddt_mean":58.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=KLF13","jax_strain_url":"https://www.jax.org/strain/search?query=KLF13"},"sequence":{"accession":"Q9Y2Y9","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9Y2Y9.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9Y2Y9/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y2Y9"}},"corpus_meta":[{"pmid":"20589685","id":"PMC_20589685","title":"MicroRNA-125a contributes to elevated inflammatory chemokine RANTES levels via targeting KLF13 in systemic lupus erythematosus.","date":"2010","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/20589685","citation_count":182,"is_preprint":false},{"pmid":"29122578","id":"PMC_29122578","title":"A carvedilol-responsive microRNA, miR-125b-5p protects the heart from acute myocardial infarction by repressing pro-apoptotic bak1 and klf13 in cardiomyocytes.","date":"2017","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/29122578","citation_count":76,"is_preprint":false},{"pmid":"11477107","id":"PMC_11477107","title":"The Sp1-like protein BTEB3 inhibits transcription via the basic transcription element box by interacting with mSin3A and HDAC-1 co-repressors and competing with Sp1.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11477107","citation_count":74,"is_preprint":false},{"pmid":"17053787","id":"PMC_17053787","title":"The Kruppel-like transcription factor KLF13 is a novel regulator of heart development.","date":"2006","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/17053787","citation_count":71,"is_preprint":false},{"pmid":"10828046","id":"PMC_10828046","title":"FKLF-2: a novel Krüppel-like transcriptional factor that activates globin and other erythroid lineage genes.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10828046","citation_count":69,"is_preprint":false},{"pmid":"11087666","id":"PMC_11087666","title":"Identification of KLF13 and KLF14 (SP6), novel members of the SP/XKLF transcription factor family.","date":"2000","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/11087666","citation_count":66,"is_preprint":false},{"pmid":"21482696","id":"PMC_21482696","title":"KLF13 sustains thymic memory-like CD8(+) T cells in BALB/c mice by regulating IL-4-generating invariant natural killer T cells.","date":"2011","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21482696","citation_count":63,"is_preprint":false},{"pmid":"12093895","id":"PMC_12093895","title":"A translational rheostat for RFLAT-1 regulates RANTES expression in T lymphocytes.","date":"2002","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/12093895","citation_count":57,"is_preprint":false},{"pmid":"12050170","id":"PMC_12050170","title":"Functional domains and DNA-binding sequences of RFLAT-1/KLF13, a Krüppel-like transcription factor of activated T lymphocytes.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12050170","citation_count":49,"is_preprint":false},{"pmid":"31112526","id":"PMC_31112526","title":"The antibiotic clofoctol suppresses glioma stem cell proliferation by activating KLF13.","date":"2019","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/31112526","citation_count":48,"is_preprint":false},{"pmid":"26085920","id":"PMC_26085920","title":"KLF13 promotes porcine adipocyte differentiation through PPARγ activation.","date":"2015","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/26085920","citation_count":48,"is_preprint":false},{"pmid":"20539070","id":"PMC_20539070","title":"Overexpression of KLF13 and FGFR3 in oral cancer cells.","date":"2010","source":"Cytogenetic and genome research","url":"https://pubmed.ncbi.nlm.nih.gov/20539070","citation_count":46,"is_preprint":false},{"pmid":"21596161","id":"PMC_21596161","title":"Homozygous deletion of chromosome 15q13.3 including CHRNA7 causes severe mental retardation, seizures, muscular hypotonia, and the loss of KLF13 and TRPM1 potentially cause macrocytosis and congenital retinal dysfunction in siblings.","date":"2011","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21596161","citation_count":43,"is_preprint":false},{"pmid":"32523679","id":"PMC_32523679","title":"KLF13 suppresses the proliferation and growth of colorectal cancer cells through transcriptionally inhibiting HMGCS1-mediated cholesterol biosynthesis.","date":"2020","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/32523679","citation_count":42,"is_preprint":false},{"pmid":"20410205","id":"PMC_20410205","title":"Functional differentiation of uterine stromal cells involves cross-regulation between bone morphogenetic protein 2 and Kruppel-like factor (KLF) family members KLF9 and KLF13.","date":"2010","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/20410205","citation_count":38,"is_preprint":false},{"pmid":"12758070","id":"PMC_12758070","title":"Functional interplay between CBP and PCAF in acetylation and regulation of transcription factor KLF13 activity.","date":"2003","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12758070","citation_count":37,"is_preprint":false},{"pmid":"10642511","id":"PMC_10642511","title":"Mouse BTEB3, a new member of the basic transcription element binding protein (BTEB) family, activates expression from GC-rich minimal promoter regions.","date":"2000","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/10642511","citation_count":34,"is_preprint":false},{"pmid":"27041562","id":"PMC_27041562","title":"KLF13 regulates the differentiation-dependent human papillomavirus life cycle in keratinocytes through STAT5 and IL-8.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/27041562","citation_count":33,"is_preprint":false},{"pmid":"36552891","id":"PMC_36552891","title":"UC-BSCs Exosomes Regulate Th17/Treg Balance in Patients with Systemic Lupus Erythematosus via miR-19b/KLF13.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36552891","citation_count":32,"is_preprint":false},{"pmid":"29843216","id":"PMC_29843216","title":"Transcription factor KLF13 inhibits AKT activation and suppresses the growth of prostate carcinoma cells.","date":"2018","source":"Cancer biomarkers : section A of Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/29843216","citation_count":31,"is_preprint":false},{"pmid":"11335124","id":"PMC_11335124","title":"Expression of Klf9 and Klf13 in mouse development.","date":"2001","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/11335124","citation_count":30,"is_preprint":false},{"pmid":"18604172","id":"PMC_18604172","title":"KLF13 influences multiple stages of both B and T cell development.","date":"2008","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/18604172","citation_count":28,"is_preprint":false},{"pmid":"29377979","id":"PMC_29377979","title":"MiR-147b inhibits cell viability and promotes apoptosis of rat H9c2 cardiomyocytes via down-regulating KLF13 expression.","date":"2018","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/29377979","citation_count":24,"is_preprint":false},{"pmid":"16303770","id":"PMC_16303770","title":"A novel functional interaction between the Sp1-like protein KLF13 and SREBP-Sp1 activation complex underlies regulation of low density lipoprotein receptor promoter function.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16303770","citation_count":23,"is_preprint":false},{"pmid":"28164238","id":"PMC_28164238","title":"KLF13 is a genetic modifier of the Holt-Oram syndrome gene TBX5.","date":"2017","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28164238","citation_count":22,"is_preprint":false},{"pmid":"24821970","id":"PMC_24821970","title":"KLF13 cooperates with c-Maf to regulate IL-4 expression in CD4+ T cells.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24821970","citation_count":20,"is_preprint":false},{"pmid":"37029927","id":"PMC_37029927","title":"Sp1-like protein KLF13 acts as a negative feedback regulator of TGF-β signaling and fibrosis.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/37029927","citation_count":19,"is_preprint":false},{"pmid":"28508896","id":"PMC_28508896","title":"Obesity-related CpG Methylation (cg07814318) of Kruppel-like Factor-13 (KLF13) Gene with Childhood Obesity and its cis-Methylation Quantitative Loci.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28508896","citation_count":19,"is_preprint":false},{"pmid":"35369534","id":"PMC_35369534","title":"A novel KLF13 mutation underlying congenital patent ductus arteriosus and ventricular septal defect, as well as bicuspid aortic valve.","date":"2022","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35369534","citation_count":16,"is_preprint":false},{"pmid":"22797700","id":"PMC_22797700","title":"Fbw7γ-mediated degradation of KLF13 prevents RANTES expression in resting human but not murine T lymphocytes.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22797700","citation_count":16,"is_preprint":false},{"pmid":"36583453","id":"PMC_36583453","title":"KLF13 overexpression protects sepsis-induced myocardial injury and LPS-induced inflammation and apoptosis.","date":"2022","source":"International journal of experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/36583453","citation_count":15,"is_preprint":false},{"pmid":"30863117","id":"PMC_30863117","title":"Downregulation of KLF13 through DNMT1-mediated hypermethylation promotes glioma cell proliferation and invasion.","date":"2019","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30863117","citation_count":15,"is_preprint":false},{"pmid":"36348434","id":"PMC_36348434","title":"Low expression of PEBP1P2 promotes metastasis of clear cell renal cell carcinoma by post-transcriptional regulation of PEBP1 and KLF13 mRNA.","date":"2022","source":"Experimental hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36348434","citation_count":15,"is_preprint":false},{"pmid":"36346048","id":"PMC_36346048","title":"KLF13 Loss-of-Function Mutations Underlying Familial Dilated Cardiomyopathy.","date":"2022","source":"Journal of the American Heart Association","url":"https://pubmed.ncbi.nlm.nih.gov/36346048","citation_count":14,"is_preprint":false},{"pmid":"33817286","id":"PMC_33817286","title":"Long noncoding RNA FTX ameliorates hydrogen peroxide-induced cardiomyocyte injury by regulating the miR-150/KLF13 axis.","date":"2020","source":"Open life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33817286","citation_count":13,"is_preprint":false},{"pmid":"35066757","id":"PMC_35066757","title":"The inhibitory effect of LINC00261 upregulation on the pancreatic cancer EMT process is mediated by KLF13 via the mTOR signaling pathway.","date":"2022","source":"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","url":"https://pubmed.ncbi.nlm.nih.gov/35066757","citation_count":13,"is_preprint":false},{"pmid":"33215447","id":"PMC_33215447","title":"KLF13 loss-of-function variation contributes to familial congenital heart defects.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33215447","citation_count":13,"is_preprint":false},{"pmid":"32034721","id":"PMC_32034721","title":"Downregulation of miR-96 suppresses the profibrogenic functions of cardiac fibroblasts induced by angiotensin II and attenuates atrial fibrosis by upregulating KLF13.","date":"2020","source":"Human cell","url":"https://pubmed.ncbi.nlm.nih.gov/32034721","citation_count":12,"is_preprint":false},{"pmid":"12848620","id":"PMC_12848620","title":"Selective modulation of the SM22alpha promoter by the binding of BTEB3 (basal transcription element-binding protein 3) to TGGG repeats.","date":"2003","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/12848620","citation_count":11,"is_preprint":false},{"pmid":"38402337","id":"PMC_38402337","title":"miR-135b Aggravates Fusobacterium nucleatum-Induced Cisplatin Resistance in Colorectal Cancer by Targeting KLF13.","date":"2024","source":"Journal of microbiology (Seoul, Korea)","url":"https://pubmed.ncbi.nlm.nih.gov/38402337","citation_count":11,"is_preprint":false},{"pmid":"32293321","id":"PMC_32293321","title":"Identification and analysis of KLF13 variants in patients with congenital heart disease.","date":"2020","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32293321","citation_count":10,"is_preprint":false},{"pmid":"32007582","id":"PMC_32007582","title":"The potential role of Krüppel-like factor 13 (Aj-klf13) in the intestine regeneration of sea cucumber Apostichopus japonicus.","date":"2020","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/32007582","citation_count":8,"is_preprint":false},{"pmid":"15716005","id":"PMC_15716005","title":"Transcriptional regulation of FKLF-2 (KLF13) gene in erythroid cells.","date":"2005","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/15716005","citation_count":8,"is_preprint":false},{"pmid":"39202416","id":"PMC_39202416","title":"Bioinformatic Evaluation of KLF13 Genetic Variant: Implications for Neurodevelopmental and Psychiatric Symptoms.","date":"2024","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/39202416","citation_count":6,"is_preprint":false},{"pmid":"32344861","id":"PMC_32344861","title":"Breakpoint Mapping of Symptomatic Balanced Translocations Links the EPHA6, KLF13 and UBR3 Genes to Novel Disease Phenotype.","date":"2020","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32344861","citation_count":6,"is_preprint":false},{"pmid":"37446365","id":"PMC_37446365","title":"KLF13 Regulates the Activity of the GH-Induced JAK/STAT Signaling by Targeting Genes Involved in the Pathway.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37446365","citation_count":5,"is_preprint":false},{"pmid":"28194012","id":"PMC_28194012","title":"A DNA methylation site within the KLF13 gene is associated with orexigenic processes based on neural responses and ghrelin levels.","date":"2017","source":"International journal of obesity (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/28194012","citation_count":5,"is_preprint":false},{"pmid":"38634445","id":"PMC_38634445","title":"KLF13 promotes VSMCs phenotypic dedifferentiation by directly binding to the SM22α promoter.","date":"2024","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/38634445","citation_count":4,"is_preprint":false},{"pmid":"40450000","id":"PMC_40450000","title":"KLF13 promotes esophageal cancer progression and regulates triacylglyceride and free fatty acid metabolism through GPIHBP1.","date":"2025","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/40450000","citation_count":3,"is_preprint":false},{"pmid":"39506084","id":"PMC_39506084","title":"KLF13 promotes SLE pathogenesis by modifying chromatin accessibility of key proinflammatory cytokine genes.","date":"2024","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/39506084","citation_count":3,"is_preprint":false},{"pmid":"34450131","id":"PMC_34450131","title":"KLF13 induces apoptotic cell clearance in Penaeus vannamei as an essential part of shrimp innate immune response to pathogens.","date":"2021","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34450131","citation_count":3,"is_preprint":false},{"pmid":"40597044","id":"PMC_40597044","title":"KLF13 promotes ferroptosis and chemosensitivity in lung adenocarcinoma.","date":"2025","source":"BMC biology","url":"https://pubmed.ncbi.nlm.nih.gov/40597044","citation_count":2,"is_preprint":false},{"pmid":"38973459","id":"PMC_38973459","title":"KLF13 restrains Dll4-muscular Notch2 axis to improve the muscle atrophy.","date":"2024","source":"Journal of cachexia, sarcopenia and muscle","url":"https://pubmed.ncbi.nlm.nih.gov/38973459","citation_count":2,"is_preprint":false},{"pmid":"40555914","id":"PMC_40555914","title":"KLF13 promotes breast cancer progression through the HTRA1 and the Hedgehog signaling pathway.","date":"2025","source":"Breast cancer (Tokyo, Japan)","url":"https://pubmed.ncbi.nlm.nih.gov/40555914","citation_count":1,"is_preprint":false},{"pmid":"41410190","id":"PMC_41410190","title":"Exosomal miR-3126-5p derived from cancer-associated fibroblasts facilitates glycolysis to accelerate NSCLC progression by targeting KLF13 to activate the SH2B1/IRS1 axis.","date":"2025","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41410190","citation_count":1,"is_preprint":false},{"pmid":"40696794","id":"PMC_40696794","title":"FBXW5 Promotes Epithelial-Mesenchymal Transition in Lung Adenocarcinoma Through the KLF13/TROAP Signaling Pathway.","date":"2025","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/40696794","citation_count":1,"is_preprint":false},{"pmid":"39808406","id":"PMC_39808406","title":"CircZMYM2 Alleviates TGF-β1-Induced Proliferation, Migration and Activation of Fibroblasts via Targeting miR-199b-5p/KLF13 Axis.","date":"2025","source":"Applied biochemistry and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/39808406","citation_count":1,"is_preprint":false},{"pmid":"38949897","id":"PMC_38949897","title":"KLF13 Attenuates Lipopolysaccharide-Induced Alveolar Epithelial Cell Damage by Regulating Mitochondrial Quality Control via Binding PGC-1α.","date":"2024","source":"Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research","url":"https://pubmed.ncbi.nlm.nih.gov/38949897","citation_count":1,"is_preprint":false},{"pmid":"41201692","id":"PMC_41201692","title":"A new KLF13 loss-of-function mutation responsible for sporadic dilated cardiomyopathy.","date":"2025","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/41201692","citation_count":0,"is_preprint":false},{"pmid":"40116212","id":"PMC_40116212","title":"Ascending E2F7a/b ratio facilitates KLF13 transcription in hepatocellular carcinoma and correlates with the abundance of binuclear hepatocytes (ABH) modulation for short-term recurrence.","date":"2025","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/40116212","citation_count":0,"is_preprint":false},{"pmid":"41278196","id":"PMC_41278196","title":"Exosomal lncRNA XR_001793654.1 in human cardiac explant-derived alleviates atrial fibrillation via abolishing the miR-107-3p-mediated KLF13 inhibition.","date":"2025","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/41278196","citation_count":0,"is_preprint":false},{"pmid":"41438085","id":"PMC_41438085","title":"KLF13-mediated CES2 upregulation via p300-dependent acetylation sensitizes gastric cancer cells to irinotecan.","date":"2025","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/41438085","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.11.19.25340573","title":"Whole genome sequence meta-analyses reveal common and rare genetic associations with critical COVID-19","date":"2025-11-21","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.19.25340573","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.02.07.636951","title":"Multiplexed CRISPRi Reveals a Transcriptional Switch Between KLF Activators and Repressors in the Maturing Neocortex","date":"2025-02-08","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.07.636951","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":33798,"output_tokens":7225,"usd":0.104885},"stage2":{"model":"claude-opus-4-6","input_tokens":11025,"output_tokens":4112,"usd":0.236888},"total_usd":0.341773,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"KLF13 (BTEB3) contains a direct repressor domain in its N-terminus that interacts with co-repressor mSin3A and histone deacetylase HDAC-1, and mediates repression also by competing with Sp1 for binding to GC-rich BTE DNA elements.\",\n      \"method\": \"Immunoprecipitation, GAL4 fusion assays, gel shift assays, reporter assays in CHO cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reciprocal Co-IP for mSin3A/HDAC-1 interaction, gel shift for DNA binding competition, functional reporter assays with multiple orthogonal methods in one study\",\n      \"pmids\": [\"11477107\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"KLF13 (RFLAT-1) has distinct N-terminal transcriptional activation (aa 1-35) and repression (aa 67-168) domains; contains two independent nuclear localization signals (one upstream of and one within the zinc fingers); binds the critical CTCCC sequence on the RANTES promoter; and synergizes with NF-κB for RANTES transcription.\",\n      \"method\": \"GAL4 fusion system, deletion analysis, site-directed mutagenesis, GFP fusion NLS mapping, gel shift/mutational analysis, reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal methods including mutagenesis, reporter assays, and direct DNA-binding analysis within one study\",\n      \"pmids\": [\"12050170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"KLF13 (RFLAT-1) protein expression is translationally regulated through its 5'-UTR in a cell-type-specific manner via cap-dependent translation involving eIF4E and its kinase Mnk1, downstream of ERK-1/2 and p38 MAP kinases.\",\n      \"method\": \"Overexpression of eIF4E, Mnk1 inhibition, kinase pathway inhibitors, quantitative PCR and protein analysis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal gain/loss-of-function experiments establishing translational regulatory mechanism\",\n      \"pmids\": [\"12093895\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CBP and PCAF co-activators acetylate KLF13 at specific lysine residues in its zinc finger domain; CBP acetylation disrupts KLF13 DNA binding, while PCAF blocks CBP-mediated acetylation to prevent this disruption, and CBP acetylation of KLF13 prevents PCAF stimulation of KLF13 DNA binding—demonstrating antagonistic and synergistic functional interplay between the two acetyltransferases.\",\n      \"method\": \"In vitro acetylation assays, gel shift assays, site-directed mutagenesis, co-activator co-expression reporter assays\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro acetylation with mutagenesis and DNA-binding assays establishing mechanistic details of PTM-dependent regulation\",\n      \"pmids\": [\"12758070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"KLF13 (BTEB3) binds to TGGG repeat motifs in the SM22α promoter and activates or inhibits reporter gene expression depending on which TGGG box it occupies; only one of three boxes is required for BTEB3-dependent activation in P19 cells; KLF13 activates the SM22α promoter in vascular smooth muscle cells (VSMCs) and is expressed in VSMCs in vitro with modulated expression after injury in vivo.\",\n      \"method\": \"Recombinant protein binding assays, mutation analysis, transient transfection reporter assays in P19 and VSMC cells\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mutation analysis and cell-type-specific reporter assays; single lab study\",\n      \"pmids\": [\"12848620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"KLF13 represses the low density lipoprotein receptor (LDLR) promoter by binding proximal LDLR DNA sequences in vivo (confirmed by ChIP) in a DNA context-selective manner; this repression is antagonized by Sp1 and SREBP, and KLF13 binding is upregulated by oxysterols.\",\n      \"method\": \"RNA interference, EMSA, ChIP, reporter assays, deletion and site-directed mutagenesis, HDAC inhibitor treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including ChIP (in vivo binding), EMSA, RNAi, and mutagenesis in one study\",\n      \"pmids\": [\"16303770\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"KLF13 binds conserved regulatory elements on cardiac promoters, activates cardiac transcription, and physically and functionally interacts with GATA-4 to synergistically activate cardiac gene expression; knockdown of KLF13 in Xenopus embryos causes atrial septal defects and hypotrabeculation similar to GATA-4 hypomorphs.\",\n      \"method\": \"Xenopus knockdown (morpholino), co-immunoprecipitation, reporter assays, in situ hybridization, promoter binding assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — physical interaction confirmed by Co-IP, functional synergy by reporter assay, and in vivo loss-of-function phenotype with epistasis to GATA-4\",\n      \"pmids\": [\"17053787\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"KLF13 deficiency in mice causes accumulation of DP thymocytes, reduction of CD4+ SP cells, altered surface expression of CD3, CD8, CD5, and HSA on DP cells consistent with TCR signaling defects, impaired peripheral T cell activation, a partial block at the CD43+ to CD43− pre-B cell transition, and increased CD21/CD23 expression on peripheral B cells.\",\n      \"method\": \"KLF13 knockout mice, flow cytometry, cell surface marker analysis\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with multiple defined cellular phenotypes across B and T cell developmental checkpoints\",\n      \"pmids\": [\"18604172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"miR-125a directly targets the 3'-UTR of KLF13 mRNA (confirmed by luciferase reporter), negatively regulates KLF13 protein expression in a dose-dependent manner, and thereby suppresses RANTES expression in activated T cells.\",\n      \"method\": \"Luciferase reporter assay, gain- and loss-of-function miRNA transfection, qPCR, ELISA\",\n      \"journal\": \"Arthritis and rheumatism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — luciferase reporter validation with multiple gain/loss-of-function methods; replicated across conditions\",\n      \"pmids\": [\"20589685\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"KLF13 participates in uterine stromal cell differentiation through cross-regulation with BMP2 and KLF9: KLF13 knockdown attenuates BMP2 expression and abrogates BMP2-mediated inhibition of KLF9, while KLF13 expression is positively associated with BMP2 and inversely with KLF9.\",\n      \"method\": \"siRNA knockdown in human endometrial stromal cells (HESCs), recombinant BMP2 treatment, KLF9 null mice, qPCR\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA with in vivo mouse null corroboration; single lab\",\n      \"pmids\": [\"20410205\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"KLF13 is required in BALB/c mice for maintenance of IL-4-generating invariant NKT (iNKT) cells; KLF13-deficient BALB/c mice have iNKT cell numbers comparable to C57BL/6 mice and extremely low levels of thymic memory-like CD8+ T cells, demonstrating that KLF13 sustains iNKT cells that produce IL-4 sufficient to drive thymic memory-like CD8+ T cell generation.\",\n      \"method\": \"KLF13 knockout mice (BALB/c background), flow cytometry, IL-4 neutralization, IL-4 supplementation\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with multiple functional rescue experiments establishing pathway position\",\n      \"pmids\": [\"21482696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"KLF13 protein is degraded in resting human T lymphocytes via GSK3β-mediated phosphorylation that triggers ubiquitination by the E3 ligase Fbw7γ; proteasomal or lysosomal inhibition stabilizes KLF13 and increases RANTES expression. This mechanism is absent in murine T cells due to lack of Fbw7γ.\",\n      \"method\": \"Proteasomal/lysosomal inhibitor treatment, GSK3β and Fbw7γ siRNA knockdown, protein analysis by western blot\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — identification of specific kinase (GSK3β) and E3 ligase (Fbw7γ) with siRNA knockdown validation and species comparison\",\n      \"pmids\": [\"22797700\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"KLF13 directly binds IL-4 promoter regions and synergizes with the transcription factor c-Maf to positively regulate IL-4 expression in CD4+ T cells; KLF13-deficient mice show reduced IL-4 and Th2 cytokine gene expression without changes in GATA3 or c-Maf levels.\",\n      \"method\": \"KLF13 knockout mice, gene expression analysis, ChIP (promoter binding), reporter/synergy assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mice with direct promoter binding demonstrated by ChIP and functional synergy assays\",\n      \"pmids\": [\"24821970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"KLF13 promotes porcine adipocyte differentiation by directly binding to a KLF13-binding site within the −593/−577 region of the porcine PPARγ proximal promoter and transactivating PPARγ expression; siRNA knockdown of KLF13 attenuates porcine adipocyte differentiation.\",\n      \"method\": \"siRNA knockdown, KLF13 overexpression, promoter deletion and mutation analysis, luciferase reporter assay\",\n      \"journal\": \"Cell & bioscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter mutagenesis and reporter assays identifying binding site; single lab, porcine model\",\n      \"pmids\": [\"26085920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"KLF13 is upregulated in HPV-positive keratinocytes via HPV E7 protein suppression of ubiquitin ligase FBW7; KLF13 is required for HPV productive life cycle by supporting STAT5 expression, which activates the ATM DNA damage pathway and IL-8 chemokine; neutralization of IL-8 diminishes viral genome amplification.\",\n      \"method\": \"shRNA knockdown, qPCR, western blot, viral genome amplification assays, IL-8 neutralization\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — shRNA knockdown with defined pathway placement (KLF13→STAT5→ATM/IL-8→viral genome amplification); single lab\",\n      \"pmids\": [\"27041562\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"KLF13 physically interacts with TBX5 via TBX5's T-domain and synergistically activates transcription of cardiac genes; disease-causing TBX5 mutations in the T-domain reduce KLF13 interaction; loss of one Klf13 allele in Tbx5 heterozygous mice significantly increases penetrance of cardiac septal defects.\",\n      \"method\": \"Co-immunoprecipitation, reporter synergy assays, genetic epistasis in double-heterozygous mice, mutagenesis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reciprocal Co-IP for physical interaction, mutagenesis of disease alleles, and in vivo genetic epistasis in double-heterozygous mice\",\n      \"pmids\": [\"28164238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The antibiotic clofoctol upregulates KLF13 expression through its targeted binding protein UNR (Upstream of N-ras), an RNA-binding protein; elevated KLF13 acts as a tumor suppressor to inhibit glioma stem cell proliferation and induce apoptosis.\",\n      \"method\": \"High-throughput drug screening, target binding protein identification, downstream gene analysis, patient-derived xenografts, colony formation and apoptosis assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — identification of UNR as drug target mediating KLF13 upregulation with in vivo xenograft validation; single lab\",\n      \"pmids\": [\"31112526\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"KLF13 transcriptionally inhibits HMGCS1 promoter activity (confirmed by ChIP-qPCR and luciferase assay), reducing cholesterol biosynthesis in colorectal cancer cells; KLF13 knockdown or HMGCS1 overexpression rescues proliferation, establishing KLF13→HMGCS1→cholesterol biosynthesis as the tumor-suppressive mechanism.\",\n      \"method\": \"ChIP-qPCR, luciferase reporter assay, siRNA knockdown, overexpression, CCK-8, colony formation, cell cycle analysis, xenograft\",\n      \"journal\": \"Cell & bioscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP confirms in vivo promoter binding; functional rescue experiments; single lab\",\n      \"pmids\": [\"32523679\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"KLF13 recruits a repressor complex comprising SIN3A and HDAC1 to TGF-β target gene promoters, limiting their profibrotic induction; TGF-β transiently induces KLF13 as a negative feedback loop, but persistent TGF-β signaling reduces KLF13 through FBXW7-mediated ubiquitination degradation and HDAC-dependent transcriptional inhibition.\",\n      \"method\": \"KLF13 global knockout mice, AAV-mediated overexpression, ChIP, Co-IP for SIN3A/HDAC1 complex, reporter assays, FBXW7 interaction studies\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — KO mice with AAV rescue, Co-IP for repressor complex, ChIP for promoter binding, and identification of FBXW7 as E3 ligase; multiple orthogonal methods\",\n      \"pmids\": [\"37029927\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"KLF13 directly regulates expression of JAK/STAT pathway genes (Jak1, Jak2, Jak3, Socs1) by binding their proximal promoters; KLF13 differentially modulates GH-induced JAK/STAT signaling by decreasing the STAT3 branch while enhancing STAT5 activity; GH treatment increases nuclear KLF13 content and Klf13 mRNA.\",\n      \"method\": \"ChIP, KLF13-deficient HT22 neuronal cells, qPCR, reporter assays, GH stimulation experiments\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP confirms promoter binding; KO cell line functional analysis; single lab\",\n      \"pmids\": [\"37446365\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"KLF13 directly binds the SM22α promoter to suppress its expression, promoting vascular smooth muscle cell (VSMC) phenotypic dedifferentiation; KLF13 knockdown ameliorates intimal hyperplasia after carotid injury, at least partly through inactivation of p-AKT signaling.\",\n      \"method\": \"Bioinformatics, atherosclerotic plaque analysis (human and ApoE−/− mice), siRNA knockdown, ChIP, reporter assay, carotid injury mouse model\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and reporter confirm direct promoter binding; in vivo mouse model; single lab\",\n      \"pmids\": [\"38634445\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"KLF13 represses Dll4 transcription (confirmed by luciferase reporter assay), inhibiting the Dll4-Notch2 axis and thereby preventing muscle atrophy; dexamethasone inhibits KLF13 expression by suppressing MYOD1-mediated KLF13 transcriptional activation and promoting FBXW7-mediated KLF13 ubiquitination.\",\n      \"method\": \"Transcriptome analysis, luciferase reporter assays, KLF13 KO and overexpression in cell and mouse models, MYOD1 interaction analysis\",\n      \"journal\": \"Journal of cachexia, sarcopenia and muscle\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reporter assay confirms Dll4 as direct target; FBXW7/MYOD1 regulatory pathway identified; in vivo mouse models; single lab\",\n      \"pmids\": [\"38973459\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"KLF13 physically interacts with PGC-1α (confirmed by Co-IP) to regulate mitochondrial quality control in alveolar epithelial cells; KLF13 overexpression reduces LPS-induced inflammation and apoptosis, and PGC-1α knockdown reverses these protective effects.\",\n      \"method\": \"Co-immunoprecipitation, KLF13 overexpression, PGC-1α siRNA, MitoSOX staining, JC-1 staining, western blot\",\n      \"journal\": \"Journal of interferon & cytokine research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP identifies PGC-1α as binding partner; functional rescue establishes pathway; single lab\",\n      \"pmids\": [\"38949897\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"KLF13 directly binds the GPX4 promoter (by ChIP and dual-luciferase assay) to inhibit GPX4 transcription, thereby promoting ferroptosis in lung adenocarcinoma; overexpression of GPX4 reverses KLF13-induced ferroptosis sensitization.\",\n      \"method\": \"ChIP assay, dual-luciferase reporter assay, stable overexpression/knockdown cell lines, ROS detection, cytotoxicity assays, xenograft model\",\n      \"journal\": \"BMC biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and reporter confirm direct promoter binding; functional rescue by GPX4 re-expression; single lab\",\n      \"pmids\": [\"40597044\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"KLF13 directly binds the CES2 promoter to transcriptionally activate CES2 expression; this transcriptional activation is dependent on acetylation of KLF13 by the co-activator p300, as shown by mutagenesis and p300 inhibition; the KLF13-CES2 axis controls cellular sensitivity to irinotecan in gastric cancer.\",\n      \"method\": \"ChIP, dual-luciferase reporter assay, site-directed mutagenesis of acetylation sites, p300 inhibition, irinotecan sensitivity assays\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP, reporter assay, and mutagenesis establish direct promoter binding and p300-dependent acetylation mechanism; single lab\",\n      \"pmids\": [\"41438085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"FBXW5 promotes ubiquitin-mediated degradation of KLF13 (confirmed by CoIP); reduced KLF13 releases transcriptional repression of TROAP, facilitating EMT in lung adenocarcinoma; KLF13 directly represses TROAP transcription as shown by ChIP and luciferase assays.\",\n      \"method\": \"Co-immunoprecipitation, ChIP, dual luciferase reporter assay, siRNA/overexpression, western blot, xenograft model\",\n      \"journal\": \"Molecular carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — CoIP identifies FBXW5 as E3 ligase; ChIP and reporter confirm TROAP as direct KLF13 target; single lab\",\n      \"pmids\": [\"40696794\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"KLF13 transcriptionally represses SH2B1 expression by binding its promoter, which abolishes the SH2B1-IRS1 protein interaction (confirmed by Co-IP and GST pulldown), thereby repressing PI3K/AKT-mediated glycolysis in NSCLC cells.\",\n      \"method\": \"ChIP, dual-luciferase reporter assay, EMSA, Co-IP, GST pulldown, glycolysis assays (OCR, ECAR), xenograft model\",\n      \"journal\": \"Clinical and translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP/EMSA confirm direct promoter binding; Co-IP and GST pulldown validate SH2B1-IRS1 interaction disruption; single lab\",\n      \"pmids\": [\"41410190\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"KLF13 directly promotes GPIHBP1 transcription (confirmed by luciferase and ChIP assays), regulating triacylglyceride and free fatty acid metabolism, and promoting esophageal cancer progression through this axis.\",\n      \"method\": \"RNA-seq, ChIP-seq, ChIP-qPCR, luciferase assay, shRNA and overexpression recovery assays, xenograft model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq and ChIP-qPCR with luciferase validation; functional rescue assays; single lab\",\n      \"pmids\": [\"40450000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"KLF13 promotes HTRA1 transcription (by ChIP-seq and luciferase assays) and activates the Hedgehog signaling pathway to drive breast cancer aggressiveness and immune evasion; HTRA1 overexpression rescues the anti-tumor effects of KLF13 silencing.\",\n      \"method\": \"ChIP-seq, luciferase assay, RNA-seq, siRNA knockdown, overexpression, in vivo xenograft\",\n      \"journal\": \"Breast cancer (Tokyo, Japan)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq and luciferase confirm HTRA1 as direct target; HTRA1 rescue experiment establishes epistasis; single lab\",\n      \"pmids\": [\"40555914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"KLF13 acts as a transcriptional repressor of KLF target genes in maturing neocortical neurons, functioning as part of a transcriptional 'switch' from KLF activators (Klf6, Klf7) to repressors (Klf9, Klf13) that represses shared cytoskeletal targets including Tubb2b and Dpysl3 during postnatal neuronal maturation.\",\n      \"method\": \"Multiplexed CRISPRi knockdown in mouse neocortical neurons, chromatin accessibility analysis, gene expression profiling\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — CRISPRi with chromatin accessibility and gene expression readouts; preprint not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2025.02.07.636951\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"KLF13 is a Krüppel-like zinc-finger transcription factor that functions predominantly as a transcriptional repressor (via recruitment of mSin3A/HDAC1 co-repressor complexes and competition with Sp1) but also as an activator depending on promoter context; its activity is regulated post-translationally by CBP/PCAF acetylation of the zinc finger domain, GSK3β-mediated phosphorylation triggering Fbw7γ-dependent ubiquitination and degradation, and FBXW5-mediated ubiquitination; it physically interacts with cardiac co-regulators GATA-4 and TBX5 to synergistically drive cardiac gene expression, and translationally it is controlled through a 5'-UTR rheostat involving eIF4E and MAPK signaling, collectively enabling precise temporal regulation of downstream targets including RANTES/CCL5, IL-4, cardiac structural genes, HMGCS1, GPX4, and others across immune, cardiac, and epithelial cell contexts.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"KLF13 is a Krüppel-like zinc-finger transcription factor that functions as both a transcriptional activator and repressor in a promoter- and cell-type-dependent manner, orchestrating gene programs in immune cell development, cardiac morphogenesis, lipid metabolism, neuronal maturation, and tumor suppression. KLF13 represses target genes by recruiting a SIN3A–HDAC1 co-repressor complex and by competing with Sp1 for GC-rich DNA elements, while it activates transcription through synergistic interactions with GATA-4, TBX5, c-Maf, and p300/PCAF-mediated acetylation [PMID:11477107, PMID:17053787, PMID:28164238, PMID:24821970, PMID:41438085]. KLF13 protein abundance is tightly regulated post-translationally by GSK3β-mediated phosphorylation triggering FBXW7-dependent proteasomal degradation, by FBXW5-mediated ubiquitination, and translationally through a 5′-UTR mechanism involving eIF4E and MAPK signaling [PMID:22797700, PMID:40696794, PMID:12093895]. In vivo, KLF13 deficiency causes atrial septal defects and hypotrabeculation in Xenopus, exacerbates cardiac septal defects when combined with Tbx5 haploinsufficiency in mice, impairs T and B cell development, reduces IL-4 and Th2 cytokine production, and disrupts iNKT cell maintenance [PMID:17053787, PMID:28164238, PMID:18604172, PMID:21482696, PMID:24821970].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Establishing that KLF13 is a direct transcriptional repressor resolved how this Krüppel-like factor silences GC-rich promoters: through an N-terminal repressor domain that recruits the mSin3A–HDAC1 co-repressor complex and competition with Sp1 for DNA binding.\",\n      \"evidence\": \"Co-IP, GAL4 fusion/reporter assays, and gel shift in CHO cells\",\n      \"pmids\": [\"11477107\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether mSin3A/HDAC1 recruitment is required at all endogenous KLF13 target promoters\", \"No genome-wide target identification at this stage\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Mapping of separable activation and repression domains, dual nuclear localization signals, and the critical RANTES promoter binding site established KLF13 as a modular transcription factor with context-dependent output, while the concurrent discovery of 5′-UTR-mediated translational control via eIF4E and MAPK signaling revealed a major post-transcriptional layer governing KLF13 protein levels.\",\n      \"evidence\": \"GAL4 deletion/mutagenesis, GFP-NLS mapping, gel shift, reporter assays; eIF4E overexpression, Mnk1/MAPK inhibitors, qPCR/protein analysis in T cells\",\n      \"pmids\": [\"12050170\", \"12093895\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of translational vs. post-translational control in different cell types\", \"Identity of RNA-binding proteins mediating 5′-UTR regulation\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrating that CBP and PCAF acetylate KLF13's zinc finger domain with opposing effects on DNA binding established that post-translational acetylation serves as a molecular switch modulating KLF13 transcriptional activity.\",\n      \"evidence\": \"In vitro acetylation assays, gel shifts, site-directed mutagenesis, co-activator co-expression reporter assays\",\n      \"pmids\": [\"12758070\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo acetylation dynamics at endogenous targets\", \"Whether acetylation status differs between activation and repression contexts\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"ChIP-based demonstration that KLF13 binds the LDLR promoter in vivo, repressing it in a manner antagonized by Sp1/SREBP and upregulated by oxysterols, placed KLF13 within cholesterol homeostasis pathways and validated the Sp1-competition model at an endogenous locus.\",\n      \"evidence\": \"ChIP, EMSA, RNAi, reporter assays, HDAC inhibitor treatment\",\n      \"pmids\": [\"16303770\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Systemic lipid phenotype in KLF13 knockout animals\", \"Interplay with other KLFs on lipid-related promoters\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Discovery that KLF13 physically interacts with GATA-4 and synergistically activates cardiac gene expression, and that KLF13 morpholino knockdown in Xenopus causes atrial septal defects, established KLF13 as a cardiac transcription factor essential for heart morphogenesis.\",\n      \"evidence\": \"Co-IP, reporter synergy assays, Xenopus morpholino knockdown, in situ hybridization\",\n      \"pmids\": [\"17053787\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cardiac phenotype in mammalian KLF13 knockouts not yet reported at this time\", \"Whether KLF13 mutations cause human congenital heart disease\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"KLF13 knockout mice revealed that KLF13 is required for normal T cell maturation (DP-to-SP transition), peripheral T cell activation, and B cell development, establishing broad immune system functions beyond the previously known RANTES regulation.\",\n      \"evidence\": \"KLF13 knockout mice, flow cytometry, surface marker analysis\",\n      \"pmids\": [\"18604172\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets mediating each immune checkpoint defect\", \"Redundancy with other KLF family members in immune cells\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identification of miR-125a as a direct negative regulator of KLF13 mRNA via its 3′-UTR added a microRNA-mediated layer to KLF13 regulation and linked dysregulated KLF13/RANTES to autoimmune pathology in SLE T cells.\",\n      \"evidence\": \"Luciferase reporter, gain/loss-of-function miRNA transfection, ELISA in activated T cells\",\n      \"pmids\": [\"20589685\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other miRNAs cooperatively regulate KLF13\", \"In vivo confirmation of miR-125a–KLF13 axis in autoimmune models\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrating that KLF13 maintains IL-4-producing iNKT cells in BALB/c mice, and that KLF13 deficiency phenocopies IL-4 neutralization for thymic memory CD8+ T cell generation, positioned KLF13 upstream of IL-4 in a strain-specific innate-adaptive immune circuit.\",\n      \"evidence\": \"KLF13 KO on BALB/c background, IL-4 neutralization and supplementation, flow cytometry\",\n      \"pmids\": [\"21482696\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether KLF13 directly drives IL-4 transcription or acts indirectly through iNKT cell survival\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identification of GSK3β-mediated phosphorylation followed by Fbw7γ-dependent ubiquitination as the mechanism controlling KLF13 protein degradation in resting human T cells revealed the primary post-translational destruction pathway and explained species-specific differences in RANTES kinetics.\",\n      \"evidence\": \"Proteasomal/lysosomal inhibitors, GSK3β and Fbw7γ siRNA, western blot in human vs. murine T cells\",\n      \"pmids\": [\"22797700\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise phosphodegron residues on KLF13\", \"Whether Fbw7α/β isoforms also target KLF13 in non-lymphoid tissues\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"ChIP-confirmed direct binding of KLF13 to IL-4 promoter regions, combined with synergy with c-Maf, resolved the earlier question of whether KLF13 directly activates IL-4 transcription in CD4+ T cells.\",\n      \"evidence\": \"KLF13 KO mice, ChIP, reporter/synergy assays, gene expression analysis\",\n      \"pmids\": [\"24821970\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether KLF13 regulates IL-4 in iNKT cells through the same mechanism as in CD4+ T cells\", \"Genome-wide KLF13 binding landscape in T cells\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Physical interaction of KLF13 with TBX5 and genetic epistasis in double-heterozygous mice linked KLF13 to Holt-Oram syndrome biology and demonstrated that KLF13 haploinsufficiency sensitizes to cardiac septal defects in the Tbx5 heterozygous background.\",\n      \"evidence\": \"Co-IP, reporter synergy assays, disease-causing TBX5 mutagenesis, Klf13+/−;Tbx5+/− double-heterozygous mice\",\n      \"pmids\": [\"28164238\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether human KLF13 mutations cause congenital heart disease independently\", \"Structural basis of the KLF13–TBX5 interaction\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"ChIP-confirmed direct repression of HMGCS1 by KLF13 established a cholesterol biosynthesis–dependent tumor-suppressive mechanism in colorectal cancer, expanding the functional repertoire from LDLR regulation to mevalonate pathway control.\",\n      \"evidence\": \"ChIP-qPCR, luciferase assay, siRNA knockdown, overexpression rescue, xenograft\",\n      \"pmids\": [\"32523679\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether KLF13 coordinately represses multiple mevalonate pathway genes\", \"Confirmation in independent cohorts or labs\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstration that KLF13 recruits SIN3A–HDAC1 to TGF-β target gene promoters as a negative feedback brake on fibrosis, and that persistent TGF-β signaling degrades KLF13 via FBXW7, unified the repressor complex and ubiquitination mechanisms into a coherent anti-fibrotic circuit.\",\n      \"evidence\": \"KLF13 global KO mice, AAV-mediated rescue, Co-IP for SIN3A/HDAC1, ChIP, FBXW7 interaction studies\",\n      \"pmids\": [\"37029927\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific fibrotic phenotypes in KLF13 KO mice beyond those tested\", \"Whether KLF13 loss contributes to human fibrotic diseases\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Discovery that KLF13 directly represses Dll4 transcription to inhibit the Dll4-Notch2 axis in muscle, and that dexamethasone degrades KLF13 via FBXW7 while also suppressing MYOD1-driven KLF13 transcription, revealed KLF13 as a protective factor against glucocorticoid-induced muscle atrophy.\",\n      \"evidence\": \"KLF13 KO and overexpression in cell and mouse models, luciferase reporter, MYOD1 interaction analysis\",\n      \"pmids\": [\"38973459\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether FBXW7 targets the same phosphodegron as in T cells\", \"In vivo rescue of dexamethasone atrophy by KLF13 overexpression not independently confirmed\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Multiple concurrent studies identified new direct KLF13 targets (GPX4, CES2, TROAP, SH2B1, GPIHBP1, HTRA1) across cancer types, and identified FBXW5 as an additional E3 ligase for KLF13, broadening the target repertoire to ferroptosis, drug metabolism, EMT, glycolysis, and lipid metabolism while expanding the ubiquitin ligase landscape.\",\n      \"evidence\": \"ChIP/ChIP-seq, luciferase assays, Co-IP for FBXW5, functional rescue experiments, xenograft models across lung, gastric, esophageal, and breast cancer lines\",\n      \"pmids\": [\"40597044\", \"41438085\", \"40696794\", \"41410190\", \"40450000\", \"40555914\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Most findings from single labs; independent replication needed\", \"Genome-wide ChIP-seq in normal tissues to distinguish direct from cancer-context targets\", \"Structural basis for KLF13 recognition by FBXW5 vs. FBXW7\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A unified genome-wide map of KLF13 binding across tissues, the structural basis for promoter-context-dependent activation versus repression switching, and whether human KLF13 loss-of-function variants cause congenital heart disease or immunodeficiency remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal or cryo-EM structure of KLF13 alone or in complex\", \"No human genetics study identifying causative KLF13 mutations in disease\", \"No systematic comparison of KLF13 vs. KLF9 target overlap genome-wide\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 1, 4, 5, 6, 12, 17, 23]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 5, 6, 12, 13, 17, 18, 23, 24, 25, 26, 27, 28, 29]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 5, 19]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0074160\", \"supporting_discovery_ids\": [0, 1, 5, 6, 12, 13, 17, 18, 23, 24, 25, 26, 27, 28, 29]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [7, 8, 10, 12]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [6, 15]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [19, 26]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [3, 11, 21, 25]}\n    ],\n    \"complexes\": [\n      \"SIN3A–HDAC1 co-repressor complex\"\n    ],\n    \"partners\": [\n      \"SIN3A\",\n      \"HDAC1\",\n      \"GATA4\",\n      \"TBX5\",\n      \"FBXW7\",\n      \"FBXW5\",\n      \"PGC1A\",\n      \"CBP\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}